jRCT2080224856已完成2 期
A Multi-Center Study to Characterize the Long-Term Safety and Efficacy of BMS-986165 in Subjects with Systemic Lupus Erythematosus
Bristol-Myers Squibb1 个研究点目标入组 360 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 360
- 试验地点
- 1
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 干预模型
- Allocation: Randomized Intervention Model: Parallel Assignment Primary Purpose: Treatment
- 主要目的
- Treatment Purpose
入排标准
- 年龄范围
- 18age old over 至 75age old under（—）
- 性别
- All
入选标准
- •Completion of SLE Study (NCT03252587) through the protocol-required treatment period, and currently receiving blinded study drug. Note: If a subject is not receiving blinded study drug due to exceptional circumstances (eg, missed investigational product [IP] due to COVID-19 pandemic, delays in study approval, etc), the subject may be allowed to enroll with approval from the BMS Clinical Trial Physician or designee.
排除标准
- •'-Any disease or medical condition that, in the opinion of the investigator, would make the subject unsuitable for this study, would interfere with the interpretation of subject safety or study results, or considered unsuitable by the investigator for any other reason
- •Evidence of active tuberculosis (TB)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Long-Term Safety and Efficacy of BMS-986165 in Subjects with Psoriasis (IM011-075)jRCT2080224973Bristol-Myers Squibb60
已完成
2 期
Phase 2 Study of the Efficacy and Safety of BMS-986278 in Pulmonary Fibrosis (IM027-040)Pulmonary FibrosisjRCT2080225297Bristol-Myers Squibb360
招募中
1 期
A Phase 1b/2 Study of BMS-986442 with Nivolumab with or without Chemotherapy in Solid Tumors and Non-small Cell Lung CancerSolid Tumor, Non-small cell lung cancerMedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2022-503108-26-00Bristol-Myers Squibb Services Unlimited Company245
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab in Patients with Advanced CancersEUCTR2018-000340-26-GBBristol-Myers Squibb International Corporation800
进行中（未招募）
1 期
An Investigational Immuno-Therapy Study of Experimental Medication BMS-986253 Given in Combination with Nivolumab in Patients with Advanced CancersEUCTR2018-000340-26-ITBRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO800